价格

CTI BIOPHARMA

501 Elliott Ave W, Seattle, Washington, 美国www.ctibiopharma.com成立于: 2014-01-01

概览

试验阶段分布

阶段

试验数

占比

1 期

42.1%

3 期

34.2%

2 期

23.7%

试验状态分布

已完成

52.6%

终止

34.2%

撤回

13.2%

药物批准

暂无批准数据

资讯

X4 Pharmaceuticals Secures $60 Million Financing and Installs New Leadership Team

- X4 Pharmaceuticals announced a $60 million private placement financing led by Coastlands Capital, Bain Capital Life Sciences, and New Enterprise Associates to support continued development of mavorixafor. - The company simultaneously appointed a new leadership team including Dr. Adam Craig as Executive Chairman, John Volpone as President, and David Kirske as Chief Financial Officer, all formerly of CTI BioPharma. - The financing will fund continued development toward potential approval of mavorixafor in chronic neutropenia, in addition to commercialization of XOLREMDI for WHIM syndrome. - X4's CXCR4 antagonist mavorixafor is currently undergoing a global Phase 3 clinical trial (4WARD) in chronic neutropenic disorders while being marketed as XOLREMDI in the U.S.

Aug 12, 2025

ASCO 2025 Showcases Advances in Myelofibrosis Treatment with Novel JAK Inhibitors and Personalized Approaches

- The 2025 ASCO Annual Meeting highlighted significant progress in myelofibrosis treatment, featuring novel JAK inhibitors like momelotinib and pacritinib that offer alternatives to standard ruxolitinib therapy. - Momelotinib demonstrated superior anemia management in the MOMENTUM trial with 25% symptom response versus 9% with danazol, particularly benefiting patients with ruxolitinib-induced anemia. - Pacritinib showed consistent efficacy regardless of baseline cytopenias, making it valuable for patients with low platelet counts below 50,000/μL who have limited treatment options. - Pegylated interferons continue to play an important role with 70-80% response rates and superior molecular responses, especially beneficial for younger patients with potential disease-modifying activity.

Jun 4, 2025

返回机构列表

CTI BIOPHARMA

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（38）

Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

Study to Evaluate the Safety, Tolerability, and PK of Pacritinib

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer

To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects

Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects

Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects

药物批准

资讯

X4 Pharmaceuticals Secures $60 Million Financing and Installs New Leadership Team

ASCO 2025 Showcases Advances in Myelofibrosis Treatment with Novel JAK Inhibitors and Personalized Approaches